mic AG

  • WKN: A254W5
  • ISIN: DE000A254W52
  • Land: Deutschland

Nachricht vom 02.08.2021 | 09:15

DGAP-DD: mic AG english


Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
02.08.2021 / 09:15
The issuer is solely responsible for the content of this announcement.

1. Details of the person discharging managerial responsibilities / person closely associated

a) Name
Title:
First name: Andreas
Last name(s): Empl

2. Reason for the notification

a) Position / status
Position: Member of the managing body

b) Initial notification

3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name
mic AG

b) LEI
5299002CFPVFWJVMBK43 

4. Details of the transaction(s)

a) Description of the financial instrument, type of instrument, identification code
Type: Share
ISIN: DE000A254W52

b) Nature of the transaction
Disposal

c) Price(s) and volume(s)
Price(s) Volume(s)
3.00 EUR 300000.00 EUR

d) Aggregated information
Price Aggregated volume
3.0000 EUR 300000.0000 EUR

e) Date of the transaction
2021-07-29; UTC+2

f) Place of the transaction
Outside a trading venue



02.08.2021 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

Aktuelle Research-Studie

IGEA Pharma N.V.

Original-Research: IGEA Pharma N.V. (von GBC AG): Kaufen

29. November 2021